Novogenia H1 FY26 operating loss narrows 4.1% to EUR 4.7 million; revenue falls 7% to EUR 25.7 million
Bitget2026/09/28 07:00- Novogenia revenue fell 7% to EUR 25.7 million in H1 2026.
- Operating loss narrowed 4.1% to EUR 4.7 million, after cost cuts; prior-year operating income had been lifted by one-off other income.
- Net result swung to a loss of EUR 2.1 million, versus profit a year earlier, after a weaker financial result.
- Cash and securities totaled EUR 39.8 million at June 30, 2026.
- CEO Daniel Wallerstorfer said core genetics and personalized health products improved; the group launched MGT Plus in the U.S. and began marketing Multi-Cancer Check.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
